Quick Dispatch:
Your hengrui glp 1 Safiglipron HRS-7535 GLP-1 Receptor Agonist in Kailera IPO Pipeline | Min W. posted on the topic orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your hengrui glp 1 Safiglipron HRS-7535 GLP-1 Receptor Agonist in Kailera IPO Pipeline | Min W. posted on the topic ships.
Need Help?
Questions about hengrui glp 1 Safiglipron HRS-7535 GLP-1 Receptor Agonist in Kailera IPO Pipeline | Min W. posted on the topic, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for hengrui glp 1 Safiglipron HRS-7535 GLP-1 Receptor Agonist in Kailera IPO Pipeline | Min W. posted on the topic in your area.
Hengrui Pharma and Kailera Therapeutics announce successful results from Phase 3 obesity trial in China for HRS9531, a dual GLP-1/GIP Receptor Agonist. More Info: https://t.co/sM9pNr09CH $XBI $IBB $XPH $PPH
27.22
Hefty $6 Billion Deal: Hengrui Licenses GLP-1 Portfolio to Hercules
24.73
Hengrui Pharma's Potential Rival to El Lilly's Zepbound Leads to 18% Weight Loss in Key Study
28.94
The Race Is On: Winning Smart in the Intensifying GLP-1 Market in China
25.19
Hengrui, Kailera say dual-acting obesity shot succeeds in China study
28.60
China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301)
29.92
Kailera, Hengrui to advance oral obesity drug into 2 new trials
27.78
